7月6日 - ** 药物开发商Avalo Therapeutics（AVTX.O）的股价在盘前交易中上涨2.9%，至19.40美元
** Leerink Partners首次覆盖AVTX，给予“跑赢大盘”评级，目标价38美元
** 该券商表示，AVTX的领军药物abdakibart在脓疱性汗腺炎（一种会引起疼痛性肿块和脓肿的慢性皮肤病）治疗方面具有“同类最佳潜力”
** Leerink表示，在中期研究中，abdakibart的应答率为42%-43%，而安慰剂组为26%，该绝对应答率在同类研究中名列前茅
** 该机构认为，由于该药物可能具有给药频率更低且靶向性更强的优势，因此与艾伯维（AbbVie）的竞争药物 ABBV.N 相比具有差异化优势
** Leerink称，AVTX计划于2026年下半年与美国FDA会面，并于2027年上半年启动一项晚期临床研究
** 该券商还认为，AVTX用于治疗炎症性疾病的后续抗体药物AVTX-010将带来长期上涨空间
** 截至上一交易日收盘，AVTX今年以来累计上涨3.7%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.